Rubicon Research Ltd
Rubicon Research Ltd Share Price Today: Live Updates & Key Insights
Get insights on Rubicon Research Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Rubicon Research Ltd Share Price Chart
RUBICON at 10 Jul 2026 06:03 PM Pharmaceuticals
1431.40 +24.20(+1.72%)
Lowest Today 1385.00
Highest Today 1439.00
Today's Open 1411.10
Prev. Close 1407.20
52 Week High 1468.70
52 Week Low 570.75
Rubicon Research Ltd Fundamentals
Traded Volume: 1,89,636
Market Cap(Cr): 23,672.89
Avg Traded Price 1417.76
1 Year return %
Upper Circuit 1,439
Lower Circuit 1,385
P/E TTM 96.00
P/B Ratio 18.025
Traded Value(Cr) 2714.45
EPS TTM 14.919
Book value/Share 78.070
Dividend Yield 1Y 0.00%
Rubicon Research Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Rubicon Research Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Rubicon Research Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +4.16%
1M +22.29%
3M +67.18%
1Y 0.00%
YTD +108.01%
Rubicon Research Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Rubicon Research Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 1.85L
Day Before Yesterday 2.43L
1W Avg 2.55L
1M Avg 4.55L
3M Avg 5.51L
Rubicon Research Ltd Technical Details
Rubicon Research Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 1386
Support 2 1364
Support 3 1347
Pivot Point : 1404
Resistance 1 1425
Resistance 2 1443
Resistance 3 1464
Rubicon Research Ltd Corporate Actions
Rubicon Research Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Rubicon Research Ltd’s capital allocation strategies.
All
Dividends
No Dividend has been declared by RUBICON
Bonus
No Bonus has been declared by RUBICON
Splits
No Split has been declared by RUBICON
Others
Rights No Rights has been declared by RUBICON
Rubicon Research Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Rubicon Research Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Rubicon Research Ltd's relative performance and valuation against major competitors.
Stock Name Acutaas Chemicals Ltd ₹3400.80 (-1.68%) M. Cap (Cr) 278.43 1 Yr Return (%) +201.86% P/E (TTM) 78.15 PB Ratio 16.84
Stock Name Sai Life Sciences Ltd ₹1265.00 (+2.48%) M. Cap (Cr) 268.54 1 Yr Return (%) +61.90% P/E (TTM) 76.97 PB Ratio 10.81
Stock Name Neuland Laboratories Ltd ₹19506.00 (-0.18%) M. Cap (Cr) 250.26 1 Yr Return (%) +62.98% P/E (TTM) 68.75 PB Ratio 13.35
Stock Name Rubicon Research Ltd ₹1431.40 (+1.72%) M. Cap (Cr) 236.73 1 Yr Return (%) NaN% P/E (TTM) 95.94 PB Ratio 18.37
Stock Name Piramal Pharma Ltd ₹177.16 (+3.01%) M. Cap (Cr) 235.86 1 Yr Return (%) -12.06% P/E (TTM) -72.37 PB Ratio 2.89
Stock Name Granules India Ltd ₹889.85 (+0.88%) M. Cap (Cr) 220.50 1 Yr Return (%) +85.56% P/E (TTM) 37.06 PB Ratio 4.34
Stock Name Pfizer Ltd ₹4731.40 (+3.08%) M. Cap (Cr) 216.45 1 Yr Return (%) -16.54% P/E (TTM) 29.96 PB Ratio 5.15
Rubicon Research Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Rubicon Research Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 38.71 Mar 2025 29.65 Mar 2024 83.20 Mar 2023 -79.02 Mar 2022 -37.12
PARTICULARS Investing Activities Mar 2026 -271.79 Mar 2025 -10.03 Mar 2024 -130.49 Mar 2023 -33.95 Mar 2022 -86.19
PARTICULARS Financing Activities Mar 2026 296.72 Mar 2025 -34.05 Mar 2024 45.86 Mar 2023 123.65 Mar 2022 65.22
PARTICULARS Net Cash Flow Mar 2026 65.93 Mar 2025 -14.62 Mar 2024 -1.29 Mar 2023 12.19 Mar 2022 -49.08
Rubicon Research Ltd Shareholding Pattern
This shows the ownership breakdown of Rubicon Research Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 59.86%
Public 22.57%
Other Institutions 2.88%
FII 7.54%
Mutual Funds 7.14%
About Rubicon Research Ltd
Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as `Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from `Rubicon Consultants Private Limited' to `Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002. The Company's status got converted from a Private Company to a Public Company, the name was changed from `Rubicon Research Private Limited' to `Rubicon Research Limited'. A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana. Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. The Company is driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States. It has obtained its GMP manufacturing facilities at Ambernath and Satara in Maharashtra.The Company commenced manufacturing of certain special drugs in Ambernath Manufacturing Facility in 2011. In 2016, the Company acquired majority stake by ECP III Pte Ltd. Further, it acquired majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd. in 2019. In 2021, the Company acquired the business of Meditab Specialities Limited on slump sale as a going concern. In FY 2024, the Company acquired Validus, a New Jersey headquartered marketer of brand name formulation products in the US. It commenced the manufacturing of nasal products at Ambernath Plant in 2024. The Company has acquired Pithampur Manufacturing Facility from Alkem Laboratories Ltd in 2025. The Company came up with its initial public offering of 28,405,841 equity shares of face value of Re 1 each, by raising funds aggregating to Rs 1378 crores, comprising a fresh issue of 10,313,058 equity shares aggregating to Rs 500 crores and the offer for sale of 18,092,783 equity shares aggregating to Rs 878 crores on October 13, 2025.
Chairman & Independent Directo
CHANGAVALLI VENKAT
Registered office Medone House B-75 Road No.33, Wagle Estate, Thane (West), Maharashtra, 400604
FAX :022 6141 4000
Background
Incorporation Year 1999
Face Value ₹1.00
Market Lot 1
FAQs on Rubicon Research Ltd
How to buy Rubicon Research Ltd shares?
To buy Rubicon Research Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Rubicon Research Ltd?
The company has a market capitalization of ₹23,672.89.
What is the PE & PB ratio of Rubicon Research Ltd?
PE is 96 and PB is 18.025.
What is the Rubicon Research Ltd dividend for 2025–26?
For the 2025–26 financial year, Rubicon Research Ltd declared a final dividend of 0.00% per share.